Detalle Publicación

ARTÍCULO
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
Autores: González Martín, Antonio; Alba, Emilio; Ciruelos, Eva; Cortes, Javier; Llombart, Antonio; Lluch, Ana; Andres, Raquel; Alvarez, Isabel; Manuel Aramenda, Jose; Ayala de la Pena, Francisco; Barnadas, Agusti; Batista, Norberto; Calvo, Lourdes; Galve, Elena; Garcia-Palomo, Andres; Angel Garcia-Saenz, Jose; de la Haba, Juan; Lopez, Rafael; Lopez-Vivanco, Guillermo; Martinez-Janez, Noelia; Martinez de Duenas, Eduardo; Plazaola, Arrate; Rodriguez-Lescure, Alvaro; Ruiz, Manuel; Sanchez-Rovira, Pedro; Santaballa, Ana; Angel Segui, Miguel; Tusquets, Ignasi; Zamora, Pilar; Martin, Miguel
Título de la revista: CURRENT CANCER DRUG TARGETS
ISSN: 1873-5576
Volumen: 16
Número: 5
Páginas: 415-428
Fecha de publicación: 2016
Resumen:
Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane